Company intelligence / Profile preview

Zymedi

Ownership: Private
Development stage: Phase 1

Overview

Developing ZMA001 mAb targeting KARS1 for PAH and PH-ILD in pre-clinical stage. Also has ZMC001 SM for NASH and ZMC101 SM for colorectal and lung cancer in early development stages.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularImmunologyOtherOncology
Modalities: Monoclonal antibodies (mAb)Small molecules (SM)
Industry: Biotech

Drug pipeline

4 assets

ZMA001

3 more assets in the full pipeline.

Request access →

Partnerships

Evotec SEYonsei University

Beyond the preview

Go deeper on Zymedi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zymedi.

Explore the full profile